8-K Announcements
6Material company update
May 27, 2026·SEC
Material company update
May 13, 2026·SEC
Material company update
Mar 26, 2026·SEC
Dermata Therapeutics, Inc.(DRMA)Earnings, Financials & Key Ratios
DRMA•NASDAQ
$1.17
Price updated Jun 25, 2026
AboutDermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of hyperhidrosis and aesthetic conditions. The company was incorporated in 2014 and is headquartered in San Diego, California.Show more
- Revenue$0
- EBITDA-$8M+36.7%
- Net Income-$8M+38.5%
- EPS (Diluted)-8.16+89.8%
- ROE-194.2%+37.4%
DRMA Price & Volume
Dermata Therapeutics, Inc. (DRMA) stock price & volume — 10-year historical chart
Loading chart...
Persistent Clinical Burn Challenges Capital Structure Sustainability
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Clinical trial funding shortfall
Key Thesis Takeaways
- Dermata Therapeutics remains a pre-revenue, clinical-stage entity whose valuation is tethered to the advancement of its Spongilla-derived platform.
- The company faces significant execution risk as it navigates a $75.1 million accumulated deficit and a reliance on external capital to fund ongoing R&D.
- Investors should monitor the firm's ability to extend its limited $6.9 million cash runway, as the lack of commercial revenue necessitates frequent, potentially dilutive financing to maintain operations.
Verdict Logic
the company's precarious liquidity position, evidenced by a $6.9 million cash balance against a history of consistent quarterly operating losses, suggests a high probability of further shareholder dilution.
DRMA Growth Metrics
Dermata Therapeutics, Inc. (DRMA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM38%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM93.9%
Return on Capital
10 Years-382.64%
5 Years-198.51%
3 Years-215.27%
Last Year-199.72%
DRMA Recent Earnings
Dermata Therapeutics, Inc. (DRMA) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 4/12 qtrs (33%)
Q2 2026Latest
May 13, 2026Metric
Actual
Est
EPS
$0.48+9.4%
$0.53
Rev
—
—
Q2 2026
Mar 26, 2026Metric
Actual
Est
EPS
$1.52+1.3%
$1.54
Rev
—
—
Q4 2025
Nov 14, 2025Metric
Actual
Est
EPS
$1.65-3.8%
$1.59
Rev
—
—
Q3 2025
Aug 13, 2025Metric
Actual
Est
EPS
$1.66+42.8%
$2.90
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 13, 2026 | $0.48vs $0.53+9.4% | — |
| Q2 2026 | Mar 26, 2026 | $1.52vs $1.54+1.3% | — |
| Q4 2025 | Nov 14, 2025 | $1.65vs $1.59-3.8% | — |
| Q3 2025 | Aug 13, 2025 | $1.66vs $2.90+42.8% | — |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Dermata Therapeutics, Inc. (DRMA)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1.17 | $797.42K | -0.14 | — | — | -194.2% | — | |
| $6.22 | $171.19M | -13.23 | 10.2% | -14.82% | -35.57% | — | |
| $0.64 | $82.91M | -4.00 | -10.02% | -2.03% | -9.41% | — | |
| $327.99 | $9.47B | -24.33 | -100% | — | -43.02% | — | |
| $123.53 | $9.09B | -21.12 | — | — | -42.78% | — | |
| $8.86 | $690.28M | -4.45 | — | — | -74.45% | — |
Compare DRMA vs Peers
Dermata Therapeutics, Inc. (DRMA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
DRMA SEC Filings & Documents
Dermata Therapeutics, Inc. (DRMA) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when DRMA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
DRMA Frequently Asked Questions
Dermata Therapeutics, Inc. (DRMA) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is DRMA profitable?
Dermata Therapeutics, Inc. (DRMA) reported a net loss of $7.1M for fiscal year 2025.
Dividend & Returns
What is DRMA's return on equity?
Dermata Therapeutics, Inc. (DRMA) has a return on equity (ROE) of -194.2%. Negative ROE indicates the company is unprofitable.
What is Dermata Therapeutics, Inc.'s free cash flow?
Dermata Therapeutics, Inc. (DRMA) had negative free cash flow of $8.3M in fiscal year 2025, likely due to heavy capital investments.